Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study  

Oleh:

Tershakovec, Andrew M. ; Keane, William F. ; Zhongxin, Zhang ; Lyle, Paulette A. ; Appel, Gerald B. ; and Others

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Diabetes Care vol. 31 no. 03 (Mar. 2008), page 445.
Topik: CKD; chronic kidney disease ; ESRD; end-stage renal disease ; RENAAL; Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan

Ketersediaan

Perpustakaan FK Nomor Panggil: D05.K.2008.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali